<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902574</url>
  </required_header>
  <id_info>
    <org_study_id>331-14-002</org_study_id>
    <nct_id>NCT03902574</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg</brief_title>
  <official_title>A Single Center, Open-label, Randomized, 3-arm, 3-way, Crossover Trial to Investigate the Bioequivalence of Brexpiprazole (OPC-34712) Orally Disintegrating Tablets in Healthy Adult Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the bioequivalence of brexpiprazole ODT 2 mg and brexpiprazole conventional
      tablet 2 mg
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Actual">June 18, 2019</completion_date>
  <primary_completion_date type="Actual">June 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the Maximum (Peak) plasma concentration of the drug (Cmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 12,16, 24, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve calculated to the last observable concentration at time t (AUCt)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 12,16, 24, 48, 72, 96, 120, 144, 168, 216, 264, and 312 hours postdose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy Adult Male</condition>
  <arm_group>
    <arm_group_label>Brexpiprazole ODT 2mg with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brexpiprazole ODT 2mg is administered with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole ODT 2mg without water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brexpiprazole ODT 2mg is administered without water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole conventional tablet 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brexpiprazole conventional tablet 2mg is administered with water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole ODT 2mg with water</intervention_name>
    <description>Brexpiprazole ODT 2mg is administered with water.</description>
    <arm_group_label>Brexpiprazole ODT 2mg with water</arm_group_label>
    <other_name>OPC-34712 OD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole ODT 2mg without water</intervention_name>
    <description>Brexpiprazole ODT 2mg is administered without water.</description>
    <arm_group_label>Brexpiprazole ODT 2mg without water</arm_group_label>
    <other_name>OPC-34712 OD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole conventional tablet 2mg</intervention_name>
    <description>Brexpiprazole conventional tablet 2mg is administered with water.</description>
    <arm_group_label>Brexpiprazole conventional tablet 2mg</arm_group_label>
    <other_name>OPC-34712 conventional tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese males

          -  BMI ［body weight in kg /(height in m)2］ of at least 18.5 kg/m2 and less than 25.0
             kg/m2 (as a result of at the screening examination)

          -  Capable of providing written informed consent prior to initiation of any trial-related
             procedures, and able, in the opinion of the investigator, to comply with all
             requirements of the trial

        Exclusion Criteria:

          -  Clinically significant abnormality at the time of screening (eg, significant deviation
             from reference ranges) or in medical history that, in the opinion of investigator,
             subinvestigator, or sponsor may place the subject at risk or interfere with outcome
             variables such as drug absorption, distribution, metabolism, and excretion

          -  History of serious mental disorder

          -  History of drug or alcohol abuse within 2 years prior to screening

          -  History of any significant drug allergy

          -  Use of another investigational drug within 120 days prior to the first administration
             of IMP

          -  Consumption of grapefruit, grapefruit products, Seville oranges, Seville orange
             products, Star fruit, or Star fruit products within 72 hours prior to the first
             administration of IMP or consumption of alcohol within 72 hours prior to
             administration of IMP

          -  Use of prescription, over-the-counter (OTC), or herbal medication, or vitamin
             supplements, or consumption of food or beverages containing St. John's Wort within 14
             days prior to the first administration of IMP, or use of antibiotics within 30 days
             prior to the first administration of IMP

          -  History of major surgery of the digestive tract (excluding appendectomy)

          -  Any subject who, in the judgement of the investigator or subinvestigator, should not
             participate in the trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SOUSEIKAI Hakata clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

